Detalhe da pesquisa
1.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
2.
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
J Urol
; 188(1): 103-9, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22583636
3.
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.
J Thorac Oncol
; 16(4): 665-676, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485960
4.
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Clin Cancer Res
; 15(11): 3866-71, 2009 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19458055
5.
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Eur J Cancer
; 116: 137-147, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31195357
6.
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
; 34(25): 2969-79, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27354481
7.
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
; 34(25): 2980-7, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27354485
8.
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
J Clin Oncol
; 31(14): 1740-7, 2013 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23569308